Cigna Group

CI · NYSE

$306.60+$8.10 (+2.71%)TodayMarket closed · Oct 20, 7:45 PM ET

Prev close $298.50

CI analyst rating

BuyConsensus of 17 analysts over the last 12 months. 76% rate it a buy.

Strong buy0
Buy13
Hold4
Underperform0
Sell0

12-month price target · 30 analysts

Average $344.26 (+12.3% upside)

Low: $290.88
Now: $306.60
High: $420.00

Upgrades and downgrades

The latest rating actions, newest first

CI analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Piper Sandler	Oct 2, 2026	Maintains	Overweight	$346.00 → $370.00	39%
RBC Capital	Oct 1, 2026	Maintains	Outperform	$337.00	57%
Jefferies	Aug 4, 2026	Downgrade	Buy → Hold	$336.00 → $307.00	72%
Raymond James	Aug 3, 2026	Downgrade	Strong Buy → Outperform	$350.00 → $320.00	65%
Wells Fargo	Jul 31, 2026	Maintains	Equal-Weight	$305.00 → $307.00	59%
Guggenheim	Jul 31, 2026	Maintains	Buy	$338.00 → $361.00	66%
Barclays	Jul 31, 2026	Maintains	Equal-Weight	$304.00 → $310.00	59%
Bernstein	Jul 9, 2026	Maintains	Outperform	$371.00 → $381.00	77%
Mizuho	Jun 8, 2026	Maintains	Outperform	$330.00 → $340.00	69%
Barclays	May 26, 2026	Downgrade	Overweight → Equal-Weight	$310.00 → $304.00	59%

The case for and against

Updated Oct 14, 2026

Bull case

Cigna Group is well positioned because its earnings base is increasingly anchored by higher-margin, more defensible businesses in Evernorth specialty and in Cigna Healthcare’s Select segment, where self-funded smaller employers remain an underpenetrated growth pool. Management’s 10.0%-14.0% long-term adjusted EPS CAGR and at least $45.00 adjusted EPS floor by CY30 appear credible given the $3.0B enterprise efficiency program, roughly $50.0B of 5-year cash flow guidance, and identifiable growth drivers such as Select expansion, International, and Stop Loss repricing. Although Pharmacy Benefit Services faces contracting transition risk, the company’s scale in US and international medical membership, plus its winning of the Centene deal, supports a favorable outlook on durable earnings growth.

Bear case

Cigna Group is facing a challenging earnings transition as Evernorth’s Pharmacy Benefit Services shifts to the rebate-free Signature model, with margins already guided down to 3.0-3.5% from 3.5-4.5% and PBS growth only flat to 4.0% through CY30. The company’s ambitious 10.0-14.0% adjusted EPS CAGR target and at least 10.0% EPS growth in CY27 look difficult to underwrite given high execution risk, potential customer resistance to higher administrative fees, and uncertainty around network contracting and medical cost trends. Although specialty businesses like CuraScript are growing quickly and the company has scale with 16 million US and 2 million international medical members, the dependence on a large PBS reset and concentrated contract risk creates downside if growth or margins disappoint.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.